Developing a new drug to cure chronic hepatitis B virus infection
Official title: ANTIVIRAL DRUGS TO CURE CHRONIC HEPATITIS B VIRUS INFECTION
Funded at Hbvtech · NIH-10821260 · Data updated 2026-11-12
This study is working on a new antiviral medicine to help people with chronic hepatitis B, and if you join, you could help test how well it works and if it's safe, which could lead to better treatment options for everyone dealing with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hbvtech NIH-funded |
| Lab location | 1 site (Germantown, United States) |
| Project start | April 3, 2023 |
| Project end | August 25, 2025 |
| Funding year | 2023 |
| Award (this year) | $50,000 |
| NIH project number | 75N93022C00042-P00002-9999-1 |
| Project ID | NIH-10821260 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation are individuals diagnosed with chronic hepatitis B virus infection.
✕Less likely to help
Patients who do not have chronic hepatitis B virus infection will not benefit from this research.
What this research studies
This research focuses on creating a new antiviral drug aimed at curing chronic hepatitis B virus (HBV) infection. The approach involves the development and testing of antiviral agents that target the virus effectively. Patients may be involved in clinical trials to evaluate the safety and efficacy of these new treatments, which could lead to significant improvements in managing HBV. The research aims to provide a long-term solution for individuals suffering from this chronic infection.
Why it matters
Potential benefit: If successful, this research could lead to a cure for chronic hepatitis B, significantly improving the quality of life for affected patients.
How similar studies have gone: While there have been advancements in antiviral treatments for hepatitis B, this specific approach is novel and aims to provide a definitive cure.
Where this research is happening
-
Hbvtech
Germantown, United States Active
Researchers
- Principal investigator: Zhang, Yang-Yuan — Hbvtech
- Study coordinator: Zhang, Yang-Yuan
Related research
Other NIH-funded projects on the same topics.
-
HBV immune responses in functional cure and therapies guided by CD4 T cells and B cells
This grant studies how HBV-specific CD4 T cells and B cells behave in people with hepatitis B to identify clues for achieving a functional cure.
-
Therapeutic nucleic acid vaccine for chronic hepatitis B in people with HIV/HBV co-infection
A new genetic vaccine approach is being tested to help people living with both HIV and chronic hepatitis B reduce and potentially cure their HBV infection.
-
HBV immune responses and pathways linked to functional cure
Researchers will study how HBV-specific CD4 T cells and B cells behave in people with chronic hepatitis B to find what immune changes are needed for a functional cure.
-
Nanobodies to help clear HBV surface antigen and restore immunity
A small, targeted antibody therapy using nanobodies is being explored to lower hepatitis B surface antigen in people with chronic HBV, with the goal of helping the immune system clear the infection.
-
How immune cells help control chronic hepatitis B
This research looks at how two immune cell types (CD4 T cells and B cells) in adults with hepatitis B act differently in people who clear the virus versus those with long-term infection to find clues for treatments that could lead to a functional cure.
-
Host-targeted antiviral to achieve a functional cure for chronic hepatitis B
A research project tests a new drug strategy that aims to clear signs of hepatitis B in people who have a chronic infection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.